Abbott Backs Down In Kaletra Pricing Fight

Law360, New York (April 11, 2007, 12:00 AM EDT) -- Abbott Laboratories said Tuesday it will slash the price of Kaletra by more than half in a slew of developing nations, following months of international pressure over the pharmaceutical giant's drug pricing policies in Thailand, which recently broke a patent on the HIV/AIDS treatment.

The drug maker said it will offer Kaletra, its “second-line” treatment for HIV/AIDS, to the governments of more than 40 low and low-middle income countries and nongovernmental organizations at $1,000 per patient per year.

That price tag is lower than any generic...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.